An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled HKI-272 in Healthy Male Subjects.

Trial Profile

An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled HKI-272 in Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Neratinib (Primary)
  • Indications Breast cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 11 May 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 11 May 2012 Actual initiation date changed from Apr 2008 to Mar 2008 as reported by ClinicalTrials.gov.
    • 01 May 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top